AI Insight
This study examined blood biomarkers in 484 older adults with varying cognitive states and analyzed over 6,000 plasma proteins to identify distinct biological patterns associated with Alzheimer's disease progression. Researchers linked standard clinical blood tests (measuring amyloid, tau, and other markers) to comprehensive protein profiles, revealing multiple functional modules that represent different disease processes. These protein-based modules were validated across 12 independent cohorts totaling 11,042 participants and successfully predicted cognitive decline, with one synaptic vesicle module indicating neuronal resilience up to 5 years before symptom onset.
Why it matters
The findings demonstrate that routine blood tests can be expanded to capture complex biological information about Alzheimer's progression, potentially enabling better patient stratification for clinical trials, earlier risk assessment, and more personalized monitoring of disease trajectory without requiring invasive procedures.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Alzheimer’s disease (AD) unfolds over decades preceding cognitive symptoms, and measuring the full scope of its molecular complexity remains difficult. Blood-based biomarkers of amyloid, phosphorylated tau, astrocytic reactivity and neuroaxonal injury including A{beta}42/40, p-tau181, p-tau217, GFAP and NfL enable scalable assessment of AD-related pathology and associated processes but capture only a narrow slice of the systemic biology ultimately shaping disease progression. Here we link these increasingly routine clinical assays to the plasma proteome using multi-omic linear modeling to resolve functional heterogeneity in AD progression. In 484 older adults spanning normal cognition, mild cognitive impairment (MCI) and AD, we derived proteomic signatures for each key biomarker across more than 6,000 proteins, uncovering overlapping and distinct biological processes and cell types implicated in AD with robust signal across proteomic modalities. From these we built continuous progression-focused functional modules that were consistently preserved across 12 independent cohorts comprising 11,042 participants from the Global Neurodegeneration Proteomics Consortium and that associated with cognitive decline, diagnosis and AD-relevant biology. A synaptic vesicle module marked apparent neuronal resilience as much as 5 years before estimated symptom onset. We show routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
Source: Alzheimers disease blood biomarkers reveal proteomic modules of disease progression